Myeloid leukemia cells utilize branched chain keto acids to acquire intrinsic resistance to methotrexate

Clicks: 9
ID: 338584
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #49 of 54 articles by views in The Journal of Biochemistry

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cancer reprograms cellular metabolism to support and accelerate malignant properties, which is known as cancer metabolism. The cancer metabolism has specific roles in acquiring drug resistance mechanisms in multiple types of cancer tissues. Myeloid leukemia cells deregulate branched chain amino acid (BCAA) metabolism to maintain their proliferation and undifferentiated status, but the contribution of this rewired pathway to drug resistance remains poorly understood. Here, we demonstrate that supplementation with branched chain keto acids (BCKAs), the transamination products of BCAAs, specifically attenuates methotrexate (MTX) toxicity in myeloid leukemia cells, whereas direct BCAA supplementation fails to provide a similar protective effect. Conversely, BCKA supplementation inhibits lymphoid leukemia cells, an effect potentially mediated by the activation of hypoxia-inducible factor 1α (HIF-1α). Gene expression analysis further suggests the involvement of activating transcription factor 5 (ATF5) in the BCKA-mediated rescue from MTX toxicity. Clinically, MTX serves as a standard-of-care treatment for lymphoid malignancies, whereas it typically exhibits limited efficacy against myeloid leukemia. Our results highlight a divergent, lineage-specific response to BCKAs, which may underlie metabolic basis for the intrinsic resistance of myeloid leukemia to MTX.
Reference Key
openalex_W7225242438 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Naoki Tamura, Ayuna Hattori, Kenkyo Matsuura, Takashi Sakamoto, Hiroshi Arima, Akifumi Takaori‐Kondo, Takahiro Ito
Are you one of these authors? Claim your profile
Journal The Journal of Biochemistry
Year 2026
DOI
10.1093/jb/mvag082
URL
https://doi.org/10.1093/jb/mvag082
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.